Literature DB >> 9696856

Epstein-Barr virus recombinant lacking expression of glycoprotein gp150 infects B cells normally but is enhanced for infection of epithelial cells.

C M Borza1, L M Hutt-Fletcher.   

Abstract

Glycoprotein gp150 is a highly glycosylated protein encoded by the BDLF3 open reading frame of Epstein-Barr virus (EBV). It does not have a homolog in the alpha- and betaherpesviruses, and its function is not known. To determine whether the protein is essential for replication of EBV in vitro, a recombinant virus which lacked its expression was made. The recombinant virus had no defects in assembly, egress, binding, or infectivity for B cells or epithelial cells. Infection of epithelial cells was, however, enhanced. The glycoprotein was sensitive to digestion with a glycoprotease that digests sialomucins, but no adhesion to cells that express selectins that bind to sialomucin ligands could be detected.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696856      PMCID: PMC110006     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Nasopharyngeal carcinoma. X. Presence of epstein-barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya.

Authors:  C Desgranges; H Wolf; G De-Thé; K Shanmugaratnam; N Cammoun; R Ellouz; G Klein; K Lennert; N Muñoz; H Zur Hausen
Journal:  Int J Cancer       Date:  1975-07-15       Impact factor: 7.396

2.  Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis.

Authors:  J Tanner; J Weis; D Fearon; Y Whang; E Kieff
Journal:  Cell       Date:  1987-07-17       Impact factor: 41.582

3.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

4.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

5.  Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame.

Authors:  D E Oba; L M Hutt-Fletcher
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

6.  Identification of the Epstein-Barr virus gp85 gene.

Authors:  T Heineman; M Gong; J Sample; E Kieff
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

7.  A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus.

Authors:  N Miller; L M Hutt-Fletcher
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

8.  New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma.

Authors:  L Heston; M Rabson; N Brown; G Miller
Journal:  Nature       Date:  1982-01-14       Impact factor: 49.962

9.  The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA.

Authors:  N Raab-Traub; K Flynn; G Pearson; A Huang; P Levine; A Lanier; J Pagano
Journal:  Int J Cancer       Date:  1987-01-15       Impact factor: 7.396

10.  Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene.

Authors:  C Beisel; J Tanner; T Matsuo; D Thorley-Lawson; F Kezdy; E Kieff
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

View more
  24 in total

Review 1.  The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  Mol Pathol       Date:  2000-10

Review 2.  Herpesvirus entry: an update.

Authors:  Patricia G Spear; Richard Longnecker
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  An Epstein-Barr-related herpesvirus from marmoset lymphomas.

Authors:  Y Cho; J Ramer; P Rivailler; C Quink; R L Garber; D R Beier; F Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

4.  Complete genomic sequence of an Epstein-Barr virus-related herpesvirus naturally infecting a new world primate: a defining point in the evolution of oncogenic lymphocryptoviruses.

Authors:  Pierre Rivailler; Young-Gyu Cho; Fred Wang
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Reduced prevalence of Epstein-Barr virus-related lymphocryptovirus infection in sera from a new world primate.

Authors:  Mark H Fogg; Angela Carville; Jennifer Cameron; Carol Quink; Fred Wang
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model.

Authors:  Pierre Rivailler; Hua Jiang; Young-gyu Cho; Carol Quink; Fred Wang
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Augmented latent membrane protein 1 expression from Epstein-Barr virus episomes with minimal terminal repeats.

Authors:  Allison M Repic; Mingxia Shi; Rona S Scott; John W Sixbey
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

8.  Length of Epstein-Barr virus termini as a determinant of epithelial cell clonal emergence.

Authors:  Cary A Moody; Rona S Scott; Tao Su; John W Sixbey
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  The BDLF3 gene product of Epstein-Barr virus, gp150, mediates non-productive binding to heparan sulfate on epithelial cells and only the binding domain of CD21 is required for infection.

Authors:  Liudmila S Chesnokova; Sarah M Valencia; Lindsey M Hutt-Fletcher
Journal:  Virology       Date:  2016-04-08       Impact factor: 3.616

10.  Global Mapping of O-Glycosylation of Varicella Zoster Virus, Human Cytomegalovirus, and Epstein-Barr Virus.

Authors:  Ieva Bagdonaite; Rickard Nordén; Hiren J Joshi; Sarah L King; Sergey Y Vakhrushev; Sigvard Olofsson; Hans H Wandall
Journal:  J Biol Chem       Date:  2016-04-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.